Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 17/20 | 0.67 |
| ▸ | PDE4A | P27815 | 10/20 | 0.64 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.64 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4039707 | 0.94 | PDE4A (0.68) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4037773 | 0.93 | CYP2C9 (0.62) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4046828 | 0.92 | CYP2C9 (0.62) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4042517 | 0.91 | CYP2C9 (0.60) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4039855 | 0.90 | CYP2C9 (0.61) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4214113 | 0.89 | CYP2C9 (0.59) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4037854 | 0.89 | CYP2C9 (0.61) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4040596 | 0.89 | CYP2C9 (0.63) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4039005 | 0.88 | CYP2C9 (0.61) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4035929 | 0.87 | CYP2C9 (0.68) | CYP2C9PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0679196-B1 | DNA SEQUENCING BY MASS SPECTROMETRY | SEQUENOM INC (US) | 2004-05-26 | — | — | EP | claimed |
| US-6238871-B1 | HIGH SPEED; HIGH THROUGHPUT; NO REQUIRED ELECTROPHORESIS; SANGER SEQUENCING STRATEGY, THEN DETERMINING SEQUENCE BY ALIGNING TERMINATED FRAGMENTS ACCORDING TO MOLECULAR WEIGHT | SEQUENOM, INC. | 2001-05-29 | — | — | US | claimed |
| US-5547835-A | USING THE SANGER SEQUENCING STRATEGY AND ASSEMBLING THE SEQUENCE INFORMATION BY ANALYSIS OF THE NESTED FRAGMENTS OBTAINED BY BASE-SPECIFIC CHAIN TERMINATION VIA THEIR DIFFERENT MOLECULAR MASSES | SEQUENOM, INC. (US) | 1996-08-20 | — | — | US | claimed |
| EP-0679196-A1 | DNA SEQUENCING BY MASS SPECTROMETRY | SEQUENOM, INC. (US) | 1995-11-02 | — | — | EP | claimed |
| WO-1994016101-A2 | DNA SEQUENCING BY MASS SPECTROMETRY | KOESTER HUBERT (US) | 1994-07-21 | — | — | WO | claimed |
| EP-1487797-B1 | HETERO-BRIDGE SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2009-05-27 | — | — | EP | disclosed |
| EP-1487797-B1 | HETERO-BRIDGE SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2009-05-27 | — | — | EP | disclosed |
| US-7144896-B2 | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2006-12-05 | — | — | US | disclosed |
| US-20050245513-A1 | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2005-11-03 | — | — | US | disclosed |
| EP-1487797-A1 | HETERO-BRIDGE SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003078397-A1 | HETERO-BRIDGE SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245513-A1 | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors | PDE4A, PDE4B, PDE4C | CYP2C9 476/4885PDE4A 1/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.